相关临床试验
234
56 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1946
进行中（未招募）
15
6.4%
已完成
41
17.5%
Enrolling By Invitation
2
0.8%
尚未招募
39
16.7%
招募中
64
27.4%
终止
2
0.8%
Unknown
69
29.5%
撤回
2
0.8%
暂无批准数据
- Shanghai Henlius Biotech presented results from over ten studies of serplulimab (HANSIZHUANG) at the 2025 ASCO Annual Meeting, covering lung and gastrointestinal cancers with promising efficacy data. - The phase 3 ASTRUM-005 trial showed serplulimab plus chemotherapy achieved a median overall survival of 15.8 months versus 11.1 months for placebo in extensive-stage small cell lung cancer patients. - Multiple combination studies demonstrated high objective response rates, including 92% ORR in HER2-positive gastric cancer and 74.47% ORR in metastatic pancreatic cancer when combined with targeted therapies. - Real-world studies across various cancer types confirmed the safety profile and clinical effectiveness of serplulimab-based treatments in diverse patient populations.
- New AI technology developed at University of Washington has identified hundreds of undiagnosed fatty liver disease cases by analyzing existing imaging scans, with 83% of patients with evidence of the disease lacking formal diagnosis. - Researchers have developed a blood test that can predict metabolic dysfunction-associated steatotic liver disease (MASLD) up to 16 years before symptom onset with 76% accuracy by detecting five specific proteins. - Early diagnosis of fatty liver disease is critical as the condition affects up to 42% of U.S. adults and can progress to serious complications including liver scarring, advanced liver disease, and increased cancer risk if left untreated.
